



RNS

For release: 21 September 2016

## Genedrive plc ("Genedrive" or the "Company")

### Board Change

#### Appointment of Chief Financial Officer

Genedrive plc (LSE: GDR), the near patient molecular diagnostics company, today announces that Matthew Fowler has agreed to become the Company's Chief Financial Officer and a Director to the Board. Matthew's formal start date will be communicated shortly. The Company also announces that John Rylands has decided to stand down as Financial Director and a Director of the Company at the conclusion of the 2016 Annual General Meeting. John has served as a Director of the Company since March 2002 and will work with the Company to ensure an orderly transition.

Matthew joins Genedrive with over 15 years of experience in senior positions in the manufacturing, power and support services industries. Prior to joining Genedrive, Matthew spent eight years as Group Financial Controller of Scapa Group plc, a multinational manufacturing AIM-quoted business. At Scapa Group plc, Matthew was responsible for shaping and managing finance within the Group as well as strategy development and other core processes.

Before joining Scapa Group plc, Matthew spent three years at British Nuclear Group as Finance Manager where he managed the corporate centre's finance team and was responsible for planning, reporting and accounting. Matthew trained and qualified in the audit department of Deloitte & Touche.

**Commenting on the appointment, David Budd, Chief Executive Officer of Genedrive, said:** "I am delighted to welcome Matthew to Genedrive. His recent experience in an AIM-quoted manufacturing business will no doubt be hugely valuable to Genedrive as we continue to mature as a commercial-stage near patient molecular diagnostics business."

I would like to reiterate the Board's thanks to John Rylands for his commitment and contribution to the Company over the last fourteen years, covering the period leading up to the Company's listing on AIM and thereafter. I would also thank John for his assistance to me since I joined the Company in March, this year. The Board wishes him every success in the future."

**Matthew Fowler, incoming Chief Financial Officer of Genedrive, said:** "It is a very exciting time to be joining Genedrive. I look forward to working with the team as it continues to build on the potential of its platform to bring molecular diagnostics closer to the point of need and the patient setting."

The following information is disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies:

Full name and age: Matthew John Fowler (aged 41)

Matthew Fowler does not currently hold any shares in Genedrive.

Current Directorships or Partnerships:

First Water Ltd  
First Water Ramsbury Ltd  
Porritts & Spencer Ltd  
Scapa (No. 2) Ltd  
Scapa (No. 3) Ltd  
Scapa Blackburn Ltd  
Scapa Denver (North) Ltd  
Scapa Group Holdings GmbH  
Scapa Tapes India Pvt Ltd  
Scapa UK Ltd

Previous Directorships or Partnerships:

Cable Components Ltd  
Lindsay & Williams Ltd  
Scapa Europe Ltd  
Scapa Holdings Ltd  
Scapa Polymerics Ltd

Lindsay & Williams Ltd, Scapa Europe Ltd, Scapa Holdings Ltd and Scapa Polymerics Ltd were dissolved by voluntary strike off in October 2015. Cable Components Ltd was dissolved by a voluntary winding up in April 2011.

No further information in connection with his appointment is required to be disclosed under Schedule Two, paragraph (g) of the Aim Rules for Companies.

- Ends -

For further details please contact:

**Genedrive plc**

David Budd: CEO

+44 (0)161 989 0245

**Peel Hunt LLP**

James Steel

+44 (0)207 418 8900

Oliver Jackson

**Consilium Strategic Communications**

Chris Gardner

+44 (0)203 709 5700

Matthew Neal

Laura Thornton

[genedrive@consilium-comms.com](mailto:genedrive@consilium-comms.com)

**Notes to Editors**

Genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need or point of care diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® platform and MTB/RIF test have been launched in India and a Genedrive® HCV test has been successfully assessed by the Institut Pasteur, Paris.

Genedrive plc was formerly Epistem plc and continues to provide contract research services to drug development companies under the Epistem brand name.

Further details can be found at: [www.genedriveplc.com](http://www.genedriveplc.com) and [www.genedrive.com](http://www.genedrive.com)